Join the Oncology Voice Network. Join for Free
The MSL Execution Factor (Book Review)
Medical Science Liaisons Execution Factor MSL success building relationships resilience in MSL roles

The MSL Execution Factor (Book Review)


Share This Article


Summary

In this episode, Jihad “JR” Rizkallah joins Tom Caravela to delve into the core elements of success for Medical Science Liaisons through the lens of "The Execution Factor." JR emphasizes the significance of vision, passion, and resilience in MSL roles and highlights action as the central hub for effectiveness. The conversation explores overcoming challenges, building robust relationships, and utilizing LinkedIn for meaningful connections. JR also discusses the importance of encouragement, recognition, and the ethos of paying it forward within the MSL community. The episode provides valuable insights for MSLs aiming to enhance their impact and effectiveness in the field.

My guest today is Jihad “JR” Rizkallah, Director, MSLs at Sunovion. JR discusses MSL Execution Factors based on the book by Kim Perell.

JR Shares…

👉 Why he felt compelled to do this specific book review and discussion for the MSL community
👉 What the key factors of Execution are
👉 Why vision and action are so key in your success
👉 Why and how to use relationships to excel in your career as an MSL
👉 How to be resilient and overcome challenges

Click for Source
Medical Science Liaisons, Execution Factor, MSL success, building relationships, resilience in MSL roles

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Podcast
Social Media Listening Evolved
Partner Avatar MSL Talk: Tom Caravela, Conor McGladrigan, Kevin Peterson

Social Media Listening Evolved

Podcast
How to Start Presenting Like a Pro
Partner Avatar MSL Talk: Tom Caravela

How to Start Presenting Like a Pro

Article
The Oncology Data Network (ODN): Methodology, Challenges, and Achievements
OVN Avatar Ashley Woolmore , Dirk Arnold , Jean‐Yves Blay , Christian Buske , Alfredo Carrato , Winald Gerritsen , Marc Peeters , Jesus Garcia‐Foncillas , David Kerr

The Oncology Data Network (ODN): Methodology, Challenges, and Achievements

Article
Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs
OVN Avatar Alyson Haslam, PhD; Vinay Prasad, MD, MPH

Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs

Article
Loose Regulatory Standards Portend a New Era of Imprecision Oncology
OVN Avatar Ali Raza Khaki

Loose Regulatory Standards Portend a New Era of Imprecision Oncology

Article
Expert perspectives live from ASCO® 2025
Partner Avatar iNIZIO

Expert perspectives live from ASCO® 2025

Explore OVN